Date: 2014-03-06
Type of information: Collaboration agreement
Compound: small molecule program for an undisclosed oncology target
Company: Redx Pharma (UK) Pierre Fabre Laboratories (France)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration option
Action mechanism:
Disease: skin cancers
Details: * On March 6, 2014, Redx Pharma and Pierre Fabre Laboratories have completed a collaboration and option agreement in cancer research. The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications. Pierre Fabre, the second largest French pharmaceutical company, enjoys world-class expertise in both oncology and dermatology. Its portfolio is focused on chemotherapies, monoclonal antibodies, immuno-conjugates assets at various development phases and several value-added dermatological drugs, including dedicated products for orphan and debilitating conditions such as infantile hemangiomas. The pipeline has been reinforced recently with a licensing agreement for a new cancer therapeutic in immuno-oncology, AUNP12, an immune checkpoint modulator targeting the PD-1 pathway.
Financial terms: The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as a highly significant milestone in the company\'s development.
Latest news:
